Metastatic non-small cell lung cancer: Costs associated with disease progression

American Journal of Managed Care

Volumn 14, Issue 9, 2008, Pages 565-571

  Fox, Kathleen M ^a   Brooks, John M ^b   Kim, Jennifer ^c  

^a Strategic Healthcare Solutions LLC   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HEALTH CARE COSTS; HUMANS; LUNG NEOPLASMS; MALE; MICHIGAN; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 51849133645     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. American Cancer Society. Cancer Facts & Figures 2006. http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf. Accessed September 17, 2007.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5 version 2.0. Lyon, France: IARC Press; 2004. http://www.depdb.iarc.fr/globocan/ GLOBOframe.html. Accessed August 17, 2007
3. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9(9):1618-1626.
4. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2000;2:CD002139.
5. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311(7010):899-909.
6. National Cancer Institute. Non-small cell lung cancer treatment (PDQ): health professional version. http://www.cancer.gov/cancertopics/pdq/ treatment/non-small-cell-lung/healthprofessional. Accessed March 23, 2006.
7. Kutikova L, Bowman J, Chang S, Long SR, Obasaju C, Crown WH. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer. 2005;50(2):143-154.
8. Hillner BE, McDonald K, Desch CE, et al. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort. J Clin Oncol. 1998;16(4):1420-1424.
9. Fireman BH, Quesenberry CP, Somkin CP, et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev. 1997;18(4):51-76.
10. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40(8 suppl):IV-104-IV-117
11. Schiller JH, Harrington D, Belani CP, et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002;346(2):92-98.
12. Strauss GM, Hemdon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633 [abstract]. J Clin Oncol. 2004;22:14s. Abstract 7019.
13. Horn L, Visbal A, Leighl NB. Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics. Drugs Aging. 2007;24(5):411-428.
14. Neymark N, Lianes P, Smit EF, van Meerbeeck JP. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer. Pharmacoeconomics. 2005;23(11):1155-1166.
15. Dooms CA, Lievens YN, Vansteenkiste JF. Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer. Eur Respir J. 2006;27(5):895-901.
16. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373-383.
17. Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol. 2004;171(6, pt 11:2250-2254.
18. Lamerato L, Havstad S, Gandhi S, Jones D, Nathanson D. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer. 2006;106(9):1875-1882.